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Acquired immune deficiency syndrome (AIDS)
was in part recognized because of the unusual occur-
rence of aggressive B cell lymphomas and opportunis-
tic infections in the same patients. Because the
lymphomas typically presented in advanced stage,
some of the earliest attempts at treatment were very
aggressive. It soon emerged that the complications of
chemotherapy that might be anticipated in the general
population were much more likely to occur in patients
with AIDS and lymphoma. Standard lymphoma
regimens were replaced by reduced-dose lymphoma
regimens and high-dose strategies involving stem cell
rescue were deemed inappropriate. However, with
advances in supportive care including routine use of
pneumocystis prophylaxis, leukocyte growth factors,
and effective antiretroviral therapy (ART), standard-
dose lymphoma therapies became standard for AIDS
lymphoma patients and stage for stage, outcomes
were comparable or even better than in the general
population. High-dose therapy with autologous stem
cell rescue was pursued at several centers and in small
cooperative group trials, and the results were similar to
what was achieved with high-dose therapy in the
general population. Specifically, mortality among
HIV-1-infected patients with lymphoma who went
to transplant was largely a function of relapsed or
progressive lymphoma or occasionally organ toxicity
(veno-occlusive disease) rather than opportunistic
infection. Many patients achieved sustained remission
and were likely cured. Small numbers of allogeneic
transplants followed, and in the era of effective ART
yielded encouraging results. Outcomes for a very small
number of patients appear similar to what might be
expected in the general population. Among the recip-
ients of allotransplant was a patient in Berlin withJohnsHopkins School ofMedicine, Baltimore, Maryland;
ity of Hope, Duarte, California.
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6/j.bbmt.2011.10.027acute myelogenous leukemia (AML) who received
a graft from a donor who was homozygous for a poly-
morphism that confers resistance to HIV-1 infection;
ART was discontinued and 3.5 years later it appears
that the patient was cured of AML and of HIV-1.
Hence, this special symposium is presented with a fo-
cus on aspects of HIV-1 biology, innate and adaptive
resistance, genetically engineered resistance, practical
aspects of the autologous and allogeneic hematopoi-
etic stem cell transplant, and consideration of the
possibility that the use of partially matched unrelated
donors might increase the opportunity to cure malig-
nancy as well as HIV-1 infection.NATURAL HISTORYOF HIV-1 INFECTION
HIV-1 infection is characterized by continuous
plasma viremia, a decline in CD41 T-lymphoctyes
and progression to AIDS in approximately 10 years
without treatment. Current ART decreases HIV-1
plasma RNA to undetectable levels, allows for CD4
T cell recovery, and clinical immunodeficiency can
be reversed in most individuals. This has transformed
HIV-1 infection into a chronic manageable illness.
Initially it was hoped that ART could definitively
cure infection; however, even after decades of effective
therapy, if ART is interrupted, HIV-1 viremia returns
to pretreatment levels. Thus, life-long therapy is re-
quired. Fortunately, newer generations of antiretrovirals
are increasinglymorepotent andwell tolerated;however,
because of the costs associated with life-long therapy,
the majority of HIV-infected individuals world-wide
do not have access to therapy. In addition to cost, missed
doses by patients can result in the development of drug
resistance, which requires treatment with more toxic
and difficult to administer drug regimens.HIV-1 LATENT RESERVOIR
The major barrier to HIV-1 cure by ART is
thought to be the HIV-1 latent reservoir in resting
memory CD41 T cells. HIV-1 preferentially infects
and replicates in activated CD41 T-lymphocytes. As
part of the retroviral life cycle, the HIV-1 RNA
genome is transcribed to DNA and integrated into
the host cell genome. Activated lymphocytes have
Table 1. Genetic Factors Associated with Host Control of
HIV-1 Infection
Genotype Proposed Mechanism
CCR5 delta 32 mutation Lack of coreceptor expression
necessary for HIV-1 entry
Protective HLA types
HLA B*27, HLA B*57, HLA B5801 Effective cytotoxic T cell response
HLA C SNP (235 C/C) More efficient killing by NK cells
HLA Bw4-80I subset plus KIR3DL1,
KIR3DSI
More efficient killing by NK cells
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days. However, a subset of activated CD41 T cells re-
vert to a quiescent state and persist as resting memory
CD41 T cells. This is a consequence of normal im-
mune physiology and memory T cells are designed
to survive for the life of the individual in order to pro-
tect against reinfection with previously encountered
pathogens. If an activated HIV-infected CD41 T cell
reverts to a resting memory cell before dying, it will
harbor a stably integrated HIV-1 genome for the life
of the cell. Resting memory cells are not permissive
for viral production, and in this state HIV-1 will be
latent, protected from ART and the immune system.
However, if the memory CD41 T cell encounters its
cognate antigen and becomes activated, HIV-1 pro-
duction will recur. If ART is not present, infection
can spread to new cells.
In vivo studies of patients on ART with undetect-
able plasma virus demonstrate that approximately 1 in
a million resting memory CD41 T cells harbor repli-
cation competent HIV-1. Longitudinal studies show
that because of the long half-life of these cells, the res-
ervoir size does not appreciably decay and models pre-
dict that it would take more than 70 years on ART to
achieve eradication (reviewed in [1]).NATURAL RESISTANCE TO HIV-1
ACQUISITION
The study of several cohorts of individuals who are
repeatedly exposed to HIV-1 but remain uninfected
has identified several genetic factors that may protect
against HIV-1 acquisition. These exposed seronega-
tive cohorts include groups of hemophiliacs, men
who have sex with men, commercial sex workers, and
intravenous drug users. The best describedmechanism
of protection is a 32-base pair deletion in the chemo-
kine (C-C motif) receptor 5 gene (CCR5), which re-
sults in loss of cell surface expression of this receptor.
CCR5 is used in conjunction with the CD4 T cell re-
ceptor for HIV-1 entry. The frequency of the
CCR5Δ32 allele in European populations ranges
from 5% to 15%. Homozygosity for the polymor-
phism results in a very high level of protection [2,3].
The heterozygous state affords relative protectionand is also associated with slower disease progression.
This knowledge was used to select a bone marrow
donor for an HIV-1 patient with AML (the ‘‘Berlin pa-
tient’’) referred to above. Following bone marrow
transplantation from a donor homozygous for the
CCR5Δ32 allele, the patient discontinued ART and
has had no relapse of HIV-1 plasma viremia [4,5].
This is the only reported case of HIV-1 cure.NATURAL CONTROL OF HIV-1 INFECTION
Early in the epidemic, it was recognized that
certain individuals who were infected with HIV-1
and developed antibodies did not progress to AIDS.
It has since been shown that this is a fairly heteroge-
nous group of individuals, and different subtypes
have been defined. The most general designation is
a clinical phenotype known as long-term nonprogres-
sors who maintain CD4 T cell counts .500 cells/mL
with varying degrees of viremia for at least 7 years
without ART. More rare are viremic controllers:
patients who maintain plasma virus levels of \2000
copies/mL (more than a log lower than average plasma
viremia), and finally\1% of all infected individuals are
elite suppressors or elite controllers (ECs) who have
plasma RNA levels \50 copies/mL (ie, the limit of
detection of clinical assays) (reviewed in [6]).
Although there have been some cases of long-term
nonprogressors or ECs infected with defective or
attenuated strains of HIV-1, many studies have dem-
onstrated that these individuals are infected with fully
replication competent virus but have a robust immune
response to control viremia and remain clinically
asymptomatic [7,8]. Understanding the unique host
factors that contribute to natural immune control of
HIV-1 infection in ECs is critical to vaccine design ef-
forts. A novel application of this field may be selecting
donors in cases where bonemarrow transplantation for
malignancy is needed.
There are several genetic factors that have been
proposed to contribute to host control of HIV-1 in
these unique cohorts of patients (Table 1). Large epide-
miologic studies have demonstrated that certain human
leukocyte antigen (HLA) types are overrepresented.
HLA class I molecules are responsible for presenting
viral peptides to cytotoxic CD81 T cells. A number of
studies have demonstrated that ECs have highly effec-
tive cytotoxic T lymphocyte responses against HIV.
Protective alleles that have been identified include
HLA-B*57, HLA-B5801, and HLA-B*27 [9]. A recent
genome-wide association study identified .300 single
nucleotide polymorphisms with significant association
with HIV-1 control, all of which were located within
the major histocompatibility complex [10].
In addition to the cytotoxic T lymphocyte response
of the adaptive immune system, there is also evidence
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response are associatedwith host control ofHIV-1. Be-
sides particularHLA-B allotypes, the genome-wide as-
sociation study identified a single nucleotide
polymorphism 35 kb upstream of HLA-C (235 C/C)
associated withHIV-1 control [10].HLA-C is believed
to modulate the innate response of natural killer cells
that destroy virus-infected cells. Specifically, HLA-C
is a ligand for natural killer cell immunoglobulin-like
receptors (KIR). Other polymorphisms within the
KIR locus have been observed to slow disease progres-
sion in conjunction with certain HLA-B types. HLA-B
alleles can be categorized as either Bw4orBw6depend-
ing on amino acids at position 77-83, which form part
of the binding pocket for viral peptides. KIR3DL1
and KIR3DS1, when present in conjunction with
members of the Bw4 family that contain isoleucine at
position 80 (Bw4-80I), correlate with delayed progres-
sion to AIDS [11]. The mechanisms by which these
genetic factors mediate protection are multifactorial
and still being clarified (reviewed in [12]).ENGINEERING HIV-1 RESISTANT T CELLS
HIV-1 entry requires attachment to the CD4
T cell receptor followed by interaction with a second
chemokine coreceptor, CCR5 or CXCR4. Differential
use of these 2 coreceptors determines viral tropism, re-
ferred to as R5 tropic, X4 tropic, or R5/X4 dual-tropic.
R5 variants are responsible for the vast majority of all
HIV-1 transmissions and are the dominant plasma vi-
ral species in early disease. As infection progresses to
AIDS, X4 variants, and/or dual-tropic variants in-
crease in frequency [13]. Blocking these receptors is
an attractive therapeutic strategy. However, small
molecule inhibitors of CXCR4 have been poorly toler-
ated and are not currently in development for ART
[14], possibly because of the central role of this recep-
tor in cell-trafficking and maturation. In contrast, nat-
ural loss of CCR5 expression has not been shown to
have significant deleterious effects, as demonstrated
by its relatively common frequency in Caucasians
(5%-15%). Individuals homozygous for CCR5Δ32
are protected from HIV-1 acquisition, and heterozy-
gotes have delayed progression to AIDS [2,3,15,16].
A currently approved CCR5 antagonist, maraviroc,
used to treat HIV-1, has not been shown to have seri-
ous side effects. Therefore, gene therapy approaches
that could knock down CCR5 permanently have
been in development since early in the epidemic.
Several HIV gene therapy strategies that target
CCR5 have been explored including the use of ribo-
zymes, small interfering RNA, intrakines, single-chain
antibodies, and zinc-finger nucleases (reviewed in [17]).
Many of these gene therapy approaches have been tested
in clinical trials. For patients with AIDS-relatedlymphomas, a novel strategy has been to combine
genetic engineering of mature T cells or hematopoietic
stem cells with autologous bone marrow transplants
used to treat the underlying malignancy [18].
One of the more promising therapies is a protein-
based approach using zinc-finger nuclease fusion pro-
teins. Zinc-finger nucleases have been designed to
target precise sequence motifs in the CCR5 gene [17]
as well as inCXCR4 [19]. The associated nuclease gen-
erates a double-stranded break within the genome and
upon repair, mutations are inserted, which render the
gene product nonfunctional. The mutant receptor is
not expressed on the cell surface, analogous to the phe-
notype induced by the naturally occurring CCR5Δ32
polymorphism and the genetically altered T cell is re-
sistant to HIV-1 [17]. In vivo, it is hypothesized these
mutated T cells will have a survival advantage in the
presence of HIV-1 replication and selectively outgrow
susceptible T cells. Although anti-HIV efficacy has not
been clearly established, there is a precedent for the
safety and feasibility of these approaches and the field
is growing significantly.PRACTICAL ASPECTS OF AUTOLOGOUS
ANDALLOGENEIC TRANSPLANTATION FOR
PATIENTS WITH HIV-1 INFECTION
Although ultimately there may be a role for cellular
therapies with or without associated genetic manipula-
tion in the treatment ofHIV-1 infection per se, at pres-
ent autologous or allogeneic hematopoietic stem cell
transplantation is only appropriate in the setting of
a malignancy or other condition that is recognized as
a standard indication for transplantation. Two case-
control studies have investigated survival in HIV-1-
infected patients and uninfected patients undergoing
autologous transplant for lymphoma [20,21]. The
European Group for Blood and Bone Marrow
Transplantation evaluated outcomes of HIV-1-
infected patients with non-Hodgkin lymphoma
(NHL) (35) and Hodgkin lymphoma (18) and the
same number of case-controls without HIV-1 infec-
tion. City of Hope investigators reported a similar
single instutition study that included only HIV-1-
infected NHL patients (29) and uninfected NHL
controls (29). The causes of death in each of these stud-
ies are summarized in Table 2 and demonstrate similar
outcomes. There are some special considerations in
the evaluation of HIV-1-infected patients for trans-
plantation and in planning treatment [20,22-25].
What follows highlights some of the relevant
considerations. Partnering with an infectious disease
consultant(s) is a prerequisite for the management of
HIV patients through transplantation.
Consideration of transplantation for treatment of
malignancy is only appropriate in patients for whom
it is anticipated that the HIV-1 itself can be controlled.
Table 2. Outcomes of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in Case-Control Studies
Diagnosis
EBMT [20] COH [19]
HIV Lymphoma Control Lymphoma HIV NHL Control NHL
Number of patients 53 53 29 29
Deaths 19 (36%) 14 (26.5%) 8 (28%) 10 (34%)
Relapse/progression 13 (69%) 13 (93%) 4 (50%) 8 (80%)
Deaths not related to malignancy (infection, interstitial pneumonitis, unknown) 5 (26%) 1 (7%) 3 (10%) 1 (3%)
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troviral resistance are commonly used in this assess-
ment. The CD41 T cell count serves as an indicator
of cellular immune function and is a predictor of infec-
tious deaths in association with cytotoxic chemother-
apy. However, it is important to understand that
after the initiation of cytotoxic chemotherapy, CD41
T cells remain low for weeks or months and are not
necessarily indicative of long-term immune function.
In patients who are na€ıve to ART, an increase in
CD4 T cell counts may be expected. In the allogeneic
setting, host CD41T cells may be irrelevant except in-
sofar as a very low counts identify patients more likely
to harbor opportunistic pathogens that may be life
threatening in the peritransplant period. The HIV-1
RNA load is also an important measure of disease
and predictor of survival in many settings. As with
CD41 T cells, patients who are na€ıve to ART will
respond to therapy. Some patients who have failed par-
ticular regimens may respond to alternative regimens.
Thus, caution is appropriate in excluding patients
from transplant on the basis of either CD41 T cells
or HIV-1 RNA load. In the Bone Marrow Transplant
Clinical Trials Network 903 allogeneic transplant pro-
tocol, patients with a detectable viral load .750
copies/mL are required to have anHIV drug resistance
assay (HIV-1 genotype). The results of the assay are
used to assist in making a determination as to whether
HIV viremia could potentially be suppressed with
alternate ART.
Antiretroviral drugs have a multitude of physio-
logic effects and drug-drug interactions. A few key
issues are outlined below that will be of special
importance in considering transplantation. Many
antiretroviral agents may be anticipated to alter the
metabolism of drugs used in myeloablative preparative
regimens. Because these agents are already near
maximally tolerated doses, such interactions may be
associated with life-threatening toxicities. Nausea
and vomiting associated with preparative regimens
may interfere with regular antiviral dosing. Intermit-
tent ART raises concerns about the development of
a resistant strain of HIV. The combination of concerns
about drug interactions with antiretrovirals and the
preparative regimen cytotoxic agents has led some
investigators to discontinue antiretrovirals before the
initiation of the preparative regimen. Stopping ART
also requires some planning. Resistance predictablydevelops very rapidly with monotherapy, especially
with nonnucleoside reverse transcriptase inhibitors.
When combination therapy includes drugs with
different half-lives, stopping the combination results
in functional monotherapy and stopping such combi-
nations is very likely to lead to development of
resistance. Thus, when the need for stopping therapy
can be anticipated, either a ‘‘staggered stop’’ or change
in regimen such that each of the components have
similar half-lives is recommended before stopping
therapy. The issue is addressed in more detail in this
review [26].
Other specific aspects of ART as it relates to trans-
plantation need to be highlighted. Certain antiretrovi-
ral agents (eg, atazanavir, indinavir) lead to
unconjugated hyperbilirubinemia secondary to
UGT1A1 inhibition similar to that occurring with
Gilbert’s syndrome and not indicative of hepatic dys-
function [26]. Elevated total bilirubin in such patients
is not a reason for exclusion. Zidovudine (also known
as AZT) is myelosuppressive and should not be used
in the peritransplant period. Ritonavir is a potent in-
hibitor of the cytochrome P-450 CYP3A4 enzyme re-
ducing the metabolism of concomitantly administered
agents including midazolam, phenytoin, tacrolimus,
cyclosporine, rapamycin, voriconazole, and others.
Prophylaxis and management of infection is simi-
lar to that in other populations. Pneumocytis jiroveci
has been problematic in HIV patients since the begin-
ning or the epidemic but has not been a problem in
transplant studies that have included standard
trimethoprim/sulfamethoxazole prophylaxis. Shingles
has been commonly reported in trials that did not
include prophylaxis with acyclovir or similar agents.
Cytomegalovirus viremia has been reported but cyto-
megalovirus disease has not been a major source of
morbidity or mortality in these patients. In HIV-1-
infected patients outside of the transplant setting, the
major manifestations of cytomegalovirus infection
are retinitis and gastrointestinal disease. Fungal infec-
tions are a concern in HIV-1-infected patients as in
other settings.
Allogeneic transplantation raises additional con-
cerns and offers additional promise. The use of
immunosuppressive agents to prevent or treat graft-
versus-host disease might be especially problematic
in HIV-1-infected patients. However, experience
with renal transplantation has donemuch to allay these
S176 Biol Blood Marrow Transplant 18:S172-S176, 2012C. Durand et al.fears as the immunosuppressive regimens have been
well tolerated. As demonstrated by the ‘‘Berlin patient’’
allogeneic transplantation also offers the possibility
of curative therapy for HIV-1 infection in the context
of curative therapy for malignancy. The difficulties
in identifying HLA-matched donors who are also
CCR5Δ32 homozygotes explains why no other
patients have had the opportunity to follow in the
footsteps of the ‘‘Berlin patient.’’ However, the recent
demonstration that nonmyeloablative transplant using
related haploidentical donors is associated with a non-
relapse mortality of 7% at 1 year, suggests that it may
be possible to relax requirements for HLA matching
[27]. If so, it may be possible to identify CCR5Δ32
homozygous donors for HIV-1-infected patients in
the near future.ACKNOWLEDGMENTS
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